CommercialPrior AuthHigh impact
Fast Facts Newsletter - February (Special Edition) 2026
HealthPartners·MN · Endocrinology, Oncology, Rheumatology +3 more·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
HealthPartners is implementing multiple prior authorization requirements and formulary changes effective April 1, 2026, including new PA requirements for somatostatin analogs (previously no PA required for Sandostatin), oncology drugs like Vabrinty and Kyxata, and removal of Ventolin from formulary favoring generic albuterol. Several Medicare Part B drugs are now designated as non-preferred requiring step therapy.
Action Required
By April 1, 2026: Update prior authorization workflows for somatostatin analogs (Sandostatin LAR, Somatuline Depot, Signifor LAR, Somavert, Lanreotide), oncology drugs Vabrinty and Kyxata, Krystexxa, and prostaglandin intracameral implants. Update drug formulary to remove Ventolin (use generic albuterol HFA) and remove Austedo/Austedo XR (step therapy behind Ingrezza required). For Medicare patients, implement step therapy for non-preferred Part B drugs including Beizray, Durysta, iDose, Inlexzo, Kyxata, and Vabrinty. Failure to obtain required prior authorizations will result in claim denials.